Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5159MR)

This product GTTS-WQ5159MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Canlupfam IL31 gene. The antibody can be applied in Canine atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Caninized
RefSeq NM_001165914.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100302725
UniProt ID Q9N0W9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5159MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3148MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ4121MR IVTScrip™ mRNA-Anti-ICAM1, BI-505(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-505
GTTS-WQ15560MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ8891MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ11949MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ7181MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ5111MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Campath-1H
GTTS-WQ1199MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABP 980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW